ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...
ProQR Announces Results for the Second Quarter of 2017
August 16, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference. Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line...
ProQR Announces R&D Day in New York on June 15
May 09, 2017 07:00 ET
|
ProQR Therapeutics
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ETPresentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis...
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET
|
ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 07:00 ET
|
ProQR Therapeutics
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s...
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 07:00 ET
|
ProQR Therapeutics
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033QR-010 is currently being studied in 64 homozygous F508del patients in a...
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr....
ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
February 28, 2017 07:00 ET
|
ProQR Therapeutics
Key updates Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016On track to report data from the ongoing...
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
June 01, 2016 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation...